Search Results - "Mukku, S"

PHP103 Value Based Pricing in the United Kingdom - Let us Prepare for it by Mukku, S

Get full text

PHP111 Global Evidence Generation - Challenges for the Pharma Industry by Mukku, S

Get full text

OP18 Analogue Analysis - the Do's and Dont's by Mukku, S.

Get full text

Neurosyphilis presenting as rapidly progressive psychosis & dementia – A forgotten entity by Mukku, SSR, Safal, SS, Pritam, Raja, Nashi, S, Nagarathna, C, PT, Sivakumar, Netravathi, M

“…•What is Known.•Neurosyphilis is less recognised neurological complication of syphilis in the recent years due to effective use of antibiotics.•Infective…”
Get full text

PCN156 Value Based Pricing in the UK; Industry Stakeholders' Perspectives by Chate, S, Mcconkey, D, Mukku, S

Get full text

PHP35 Is Value Based Pricing Executed In Real Life Situation? – Global Perspectives by Mukku, S, Mallinson, M

Get full text

PHP131 How Can Pharma Industry Prepare Itself for the Changing Pricing and Reimbursement Landscape of Orphan Drugs in EU? by Mukku, S, Pang, F, Mcconkey, D

Get full text

PHP8 ATC Classification and Its Role in Pricing Policies by Edathodu, A.S, Mukku, S, Wild, L

Get full text

HPR153 Changing Vaccine Assessment Criteria and Focus Towards Prevention Strategies by Mukku, S., Hoxa, J., Samuel, J.

Get full text

PHP390 - Increasing Efficiency of Pricing and Market Access Decisions By Cross Functional Interactions by Mukku, S, Edathodu, A

Get full text

Increasing Efficiency of Pricing and Market Access Decisions By Cross Functional Interactions by Mukku, S, Edathodu, A

Get full text

MARKET ACCESS CHALLENGES FOR VACCINE LAUNCHES by Mukku, S, Battepati, B, Digiacomo, F, Edathodu, A

“…Objectives: Vaccine launch from a market access perspective could be more complex than launching general drugs. The study was conducted to assess the…”
Get full text

Opportunities For Pharmaceutical Companies To Successfully Launch Products In African Countries by Mukku, S, Edathodu, A, Battepatti, B, Dass, R

Get full text

PHP39 - Opportunities For Pharmaceutical Companies To Successfully Launch Products In African Countries by Mukku, S, Edathodu, A, Battepatti, B, Dass, R

Get full text

PR4 GLOBAL MARKET ACCESS STRATEGY:AN INTEGRATED APPROACH by Pang, F, Mukku, S

Get full text

PMC22 REVENUE OPTIMIZATION MODEL TO OPTIMISE POSITION AND INDICATION OF NEW LAUNCHES by Mukku, S, McConkey, D

Get full text

MARKET ACCESS CONSIDERATIONS IN PHARMACEUTICAL IN-LICENSING VALUATIONS by Ohanjanyan, A, Mukku, S, Edathodu, A, Samuel, J, Leung, SK, Digiacomo, F, Golzalez, A Olid

“…OBJECTIVES: Valuation of assets in licensing deals is based on the asset's 'approvability', with the estimated value of the asset increasing as the likelihood…”
Get full text

B37 QUALITY IMPROVEMENT IN PULMONARY AND CRITICAL CARE MEDICINE: Variability In Interpreting Severity Of Restrictive Lung Disease And Six Minute Walk Tests Among Pulmonologists: Identifying A Need For More Specific Guidelines by Anderson, T B, Duffy, J S, Kingrey, J, Mukku, S, Rivas-Perez, H, Tapyrik, S A, Bhatt, N Y, Wood, K L

Get full text

PHP30 MARKET ACCESS, AFFORDABILITY AND PRICE COMPONENTS OF MEDICINES IN THE UNITED ARAB EMIRATES (UAE) by Ansary, A, Abuelkhair, M, Mukku, S

Get full text

PR3 Industry Preparedness against German reforms by Devienne, E, White, R, Mukku, S

Get full text